
Febrile Neutropenia for Bone Marrow Transplant Patients (BMT)



Disclaimer: This clinical pathway is provided as a general guideline for use by Licensed Independent Provider's (LIP) in planning care and treatment of patients. It is not intended to be and does not establish a standard of care. Each patient's care is individualized according to specific needs.




Consider hydrocortisone (2 mg/kg X1) if patient is unstable or had a recent steroid treatment

^{*} If patient has RLQ abdominal pain consider Typhlitis and add Metronidazole 10 mg/kg (maximum 500 mg/dose)

^{**} No catheter urine cultures

^{***} Chimeric Antigen Receptor CAR T-cell therapy patients will have a wallet card with instructions about ED management of Cytokine Release Syndrome.



Vasoactive Dosing



Admit to PICU if patient requires > 2 Sodium Chloride 0.9% boluses or vasoactive agents	
 Epinephrine Drip Drug of choice for inotropy in pediatric shock Recommended to start @ 0.05 - 0.2 mcg/kg/min Titrate in small increments based on perfusion 	Epinephrine in D5 0.05 mcg/kg/min IV Continuous
Norepinephrine Drip	Norepinephrine in D5 0.05 mcg/kg/min IV Continuous
Milrinone No bolus dose; no titration Recommended to start @ 0.3 - 0.5 mcg/kg/min	Milrinone in D5 0.3 mcg/kg/min IV Continuous

Metrics



- 1. Time to first antibiotic
 - 2. Time to first bolus
- 3. Order set utilization

Contributing Members



Krystle McCarson, MD – Emergency Medicine
Tonya Thompson, MD – Emergency Medicine
Melissa Magill, MD – Emergency Medicine
Robert Saylors, MD – Hematology/Oncology
David Becton, MD – Hematology/Oncology
Arunkumar Modi, MD – Hematology/Oncology
Kevin Patton, PharmD – Pharmacy
Holly Maples, PharmD – Antimicrobial Stewardship Director
Emily Radar, RN, MSN - Clinical Effectiveness & Outcomes Manager
Sophia Blythe, MHA - Clinical Effectiveness & Outcomes Project Coordinator

References

